search
Back to results

Targeting Large-scale Networks in Depression With Real-time fMRI (Functional Magnetic Resonance Imaging) Neurofeedback

Primary Purpose

Healthy Participants

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Functional magnetic resonance imaging (fMRI)
Sponsored by
University of Michigan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Healthy Participants focused on measuring Healthy, fMRI, Neurofeedback

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria (phase 2 participants): Ability and willingness to give informed consent to participate Not taking any medication, prescription or non-prescription, with psychotropic effects (birth control medications allowed) If a woman of child-bearing age, not pregnant or trying to become pregnant No history of serious neurological illness (including, but not limited to, seizures/epilepsy) or current medical condition that could compromise brain function, such as liver failure No history of closed head injury (see protocol for more details) Ability to tolerate small, enclosed spaces without anxiety No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition Size compatible with scanner gantry Exclusion Criteria (phase 2 participants): - History of past or current mental illness (except for simple phobias), but prior history of substance dependence ok if in remission for greater than 5 years

Sites / Locations

  • University of Michigan

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Magnetic resonance imaging (MRI) group

Arm Description

Healthy volunteers will have two functional magnetic resonance imaging scans (localizer session and the real time functional magnetic resonance imaging neurofeedback session).

Outcomes

Primary Outcome Measures

Blood Oxygen Level Dependent (BOLD) signal change during the stop greater (>) RECALL contrast during the localizer session
BOLD signal change during the stop>recall contrast, comparing baseline with transfer runs (no NF in either), during the rtfMRI-NF session

Secondary Outcome Measures

Full Information

First Posted
June 28, 2023
Last Updated
September 9, 2023
Sponsor
University of Michigan
search

1. Study Identification

Unique Protocol Identification Number
NCT05934604
Brief Title
Targeting Large-scale Networks in Depression With Real-time fMRI (Functional Magnetic Resonance Imaging) Neurofeedback
Official Title
Targeting Large-scale Networks in Depression With Real-time fMRI Neurofeedback
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2023 (Anticipated)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Michigan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study is to develop a technique called real time fMRI neurofeedback. This technique uses a functional MRI scanner, except that special software allows the researchers to measure activity in participants brain, using fMRI, and then give information, in the form of a feedback signal, which indicates brain activity in real time, while in the MRI scanner. The larger goal of this study is to develop ways to help people, including those with depression, better regulate brain activity. The researchers think that this may be helpful in managing psychiatric symptoms. This study design has three phases, however, only two phases (phase 2 and 3) are considered to be a clinical trial. Therefore, this registration will include phase 2 at this time.
Detailed Description
During the second phase of the project healthy participants (approximately 12) will have three study visits (two fMRIs) over 2-4 weeks. Note: As the study is a feasibility/development study, alterations of the task design for the primary outcome measures will be done to achieve objectives of developing at task that recruits from the target region (salience network). In phase 1 of the study, changes to the task are ongoing, and the same may occur for phase 2 in order to develop a viable neurofeedback paradigm. Therefore, detailed descriptions of the outcome measures are not entered at this time, as we don't know exactly what those are. When we do, the entry will be updated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Participants
Keywords
Healthy, fMRI, Neurofeedback

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Masking Description
Phase 2 is not blinded.
Allocation
N/A
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Magnetic resonance imaging (MRI) group
Arm Type
Experimental
Arm Description
Healthy volunteers will have two functional magnetic resonance imaging scans (localizer session and the real time functional magnetic resonance imaging neurofeedback session).
Intervention Type
Other
Intervention Name(s)
Functional magnetic resonance imaging (fMRI)
Intervention Description
Healthy subjects will complete two fMRI sessions after initial assessment and training in the Recall Stop Task (RST). The first session will be the localizer session to identify the networks involved in switching in the RST. The second fMRI session, real time functional magnetic resonance imaging neurofeedback (rtfMRI-NF) session, will use localizer information from the first fMRI session to develop a mask for the rtfMRI-NF, and deliver a neurofeedback (NF) stimulus while simultaneously measuring Blood Oxygenation Level Dependent (BOLD) activity for the STOP>RECALL contrast.
Primary Outcome Measure Information:
Title
Blood Oxygen Level Dependent (BOLD) signal change during the stop greater (>) RECALL contrast during the localizer session
Time Frame
Approximately 40 minutes (during MRI)
Title
BOLD signal change during the stop>recall contrast, comparing baseline with transfer runs (no NF in either), during the rtfMRI-NF session
Time Frame
Approximately 40 minutes (during MRI)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria (phase 2 participants): Ability and willingness to give informed consent to participate Not taking any medication, prescription or non-prescription, with psychotropic effects (birth control medications allowed) If a woman of child-bearing age, not pregnant or trying to become pregnant No history of serious neurological illness (including, but not limited to, seizures/epilepsy) or current medical condition that could compromise brain function, such as liver failure No history of closed head injury (see protocol for more details) Ability to tolerate small, enclosed spaces without anxiety No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition Size compatible with scanner gantry Exclusion Criteria (phase 2 participants): - History of past or current mental illness (except for simple phobias), but prior history of substance dependence ok if in remission for greater than 5 years
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sophia Hovakimian
Phone
734-232-0129
Email
shovakim@med.umich.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Laura Stchur, MSW
Phone
734-936-1323
Email
lmarine@med.umich.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephan Taylor, MD
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophia Hovakimian, B.A.
Email
shovakim@med.umich.edu
First Name & Middle Initial & Last Name & Degree
Laura Stchur, MSW
Phone
734-936-1323
Email
lmarine@med.umich.edu
First Name & Middle Initial & Last Name & Degree
Stephan Taylor, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Targeting Large-scale Networks in Depression With Real-time fMRI (Functional Magnetic Resonance Imaging) Neurofeedback

We'll reach out to this number within 24 hrs